Private placement in Lytix Biopharma AS (NO) — NOK 100 million

Carnegie acted as joint bookrunner in connection with Lytix Biopharma AS’s NOK 100 million private placement. In addition, the company raised approx. NOK 11.3 million in a separate offering directed towards retail investors which was facilitated through collaboration between Carnegie, PrimaryBid and Nordnet Bank AB. Across the two offerings the company thus raised NOK 111.3 million.

Lytix Biopharma is a clinical-stage biotech company with a novel technology based on world-leading research in host-defense peptide-derived molecules.